Overview

Safety and Efficacy Study of Eculizumab in Shiga-Toxin Producing Escherichia Coli Hemolytic-Uremic Syndrome (STEC-HUS)

Status:
Completed
Trial end date:
2012-06-01
Target enrollment:
Participant gender:
Summary
This protocol is designed to collect safety and efficacy data on patients that have been or will be treated with eculizumab for STEC-HUS, in the context of the 2011 STEC-HUS epidemic in Germany.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Alexion Pharmaceuticals
Treatments:
Eculizumab
Shiga Toxins